1. Home
  2. MLYS vs WLDN Comparison

MLYS vs WLDN Comparison

Compare MLYS & WLDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • WLDN
  • Stock Information
  • Founded
  • MLYS 2019
  • WLDN 1964
  • Country
  • MLYS United States
  • WLDN United States
  • Employees
  • MLYS N/A
  • WLDN N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • WLDN Military/Government/Technical
  • Sector
  • MLYS Health Care
  • WLDN Consumer Discretionary
  • Exchange
  • MLYS Nasdaq
  • WLDN Nasdaq
  • Market Cap
  • MLYS 634.6M
  • WLDN 581.0M
  • IPO Year
  • MLYS 2023
  • WLDN 2006
  • Fundamental
  • Price
  • MLYS $9.97
  • WLDN $38.23
  • Analyst Decision
  • MLYS Strong Buy
  • WLDN Strong Buy
  • Analyst Count
  • MLYS 2
  • WLDN 3
  • Target Price
  • MLYS $30.00
  • WLDN $44.33
  • AVG Volume (30 Days)
  • MLYS 250.2K
  • WLDN 103.2K
  • Earning Date
  • MLYS 03-20-2025
  • WLDN 03-06-2025
  • Dividend Yield
  • MLYS N/A
  • WLDN N/A
  • EPS Growth
  • MLYS N/A
  • WLDN 802.09
  • EPS
  • MLYS N/A
  • WLDN 1.63
  • Revenue
  • MLYS N/A
  • WLDN $577,414,000.00
  • Revenue This Year
  • MLYS N/A
  • WLDN N/A
  • Revenue Next Year
  • MLYS N/A
  • WLDN $7.28
  • P/E Ratio
  • MLYS N/A
  • WLDN $23.37
  • Revenue Growth
  • MLYS N/A
  • WLDN 23.47
  • 52 Week Low
  • MLYS $8.58
  • WLDN $18.37
  • 52 Week High
  • MLYS $16.91
  • WLDN $50.00
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 40.13
  • WLDN 47.33
  • Support Level
  • MLYS $9.18
  • WLDN $37.57
  • Resistance Level
  • MLYS $10.71
  • WLDN $38.99
  • Average True Range (ATR)
  • MLYS 0.84
  • WLDN 1.02
  • MACD
  • MLYS -0.05
  • WLDN 0.31
  • Stochastic Oscillator
  • MLYS 28.72
  • WLDN 80.28

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About WLDN Willdan Group Inc.

Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.

Share on Social Networks: